Jeniel E Nett

List of Publications by Year in Descending Order

76 papers	6,009 citations	39 h-index	77 g-index
82 ext. papers	7,000 ext. citations	6.7 avg, IF	6.08 L-index

#	Paper	IF	Citations
76	Modeling Candida auris Colonization on Porcine Skin Ex Vivo. *Methods in Molecular Biology*, **2022**, 251-258	1.4	
75	Examining NeutrophilCandida auris Interactions with Human Neutrophils Ex Vivo. *Methods in Molecular Biology*, **2022**, 243-250	1.4	
74	Candida auris Cell Wall Mannosylation Contributes to Neutrophil Evasion through Pathways Divergent from Candida albicans and Candida glabrata. *MSphere*, **2021**, 6, e0040621	4.9	3
73	Priority effects dictate community structure and alter virulence of fungal-bacterial biofilms. *ISME Journal*, **2021**, 15, 2012-2027	11.6	11
72	Coordination of fungal biofilm development by extracellular vesicle cargo. *Nature Communications*, **2021**, 12, 6235	16.9	4
71	How Biofilm Growth Affects -Host Interactions. *Frontiers in Microbiology*, **2020**, 11, 1437	5.5	12
70	infection and biofilm formation: going beyond the surface. *Current Clinical Microbiology Reports*, **2020**, 7, 51-56	2.9	10
69	Lipo-chitooligosaccharides as regulatory signals of fungal growth and development. *Nature Communications*, **2020**, 11, 3897	16.9	17
68	Neutrophils From Patients With Invasive Candidiasis Are Inhibited by Biofilms. *Frontiers in Immunology*, **2020**, 11, 587956	8.2	3
67	Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Species. *MBio*, **2020**, 11,	7.6	12
66	Contributions of the Biofilm Matrix to Pathogenesis. *Journal of Fungi (Basel, Switzerland)*, **2020**, 6,	5.4	20
65	Candida auris Forms High-Burden Biofilms in Skin Niche Conditions and on Porcine Skin. *MSphere*, **2020**, 5,	4.9	31
64	Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis. *Journal of Biological Chemistry*, **2019**, 294, 2700-2713	5	10
63	Insight into Neutrophil Extracellular Traps through Systematic Evaluation of Citrullination and Peptidylarginine Deiminases. *Journal of Immunology Research*, **2019**, 2019, 2160192	4.3	24
62	Candida auris: An emerging pathogen "incognito"?. *PLoS Pathogens*, **2019**, 15, e1007638	7.4	35
61	2889. Skin Niche Conditions Trigger C. auris to Form Robust Biofilms That Resist Desiccation. *Open Forum Infectious Diseases*, **2019**, 6, S78-S78	0.9	78
60	Conserved Role for Biofilm Matrix Polysaccharides in Drug Resistance. *MSphere*, **2019**, 4,	4.9	47

59	Neutrophil extracellular traps in fungal infection. *Seminars in Cell and Developmental Biology*, **2019**, 89, 47-57	7.2	46
58	Conservation and Divergence in the Species Biofilm Matrix Mannan-Glucan Complex Structure, Function, and Genetic Control. *MBio*, **2018**, 9,	7.6	32
57	An unappreciated role for neutrophil-DC hybrids in immunity to invasive fungal infections. *PLoS Pathogens*, **2018**, 14, e1007073	7.4	34
56	Methodologies for and evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. *Microbial Cell*, **2018**, 5, 300-326	3.8	53
55	Echinocandin Treatment of Candida albicans Biofilms Enhances Neutrophil Extracellular Trap Formation. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.6	6
54	Emerging Fungal Pathogen Candida auris Evades Neutrophil Attack. *MBio*, **2018**, 9,	7.6	52
53	970. Emerging Pathogen Candida auris Evades Neutrophil Attack. *Open Forum Infectious Diseases*, **2018**, 5, S37-S37	0.9	78
52	Candida albicans FRE8 encodes a member of the NADPH oxidase family that produces a burst of ROS during fungal morphogenesis. *PLoS Pathogens*, **2017**, 13, e1006763	7.4	34
51	The Interface between Fungal Biofilms and Innate Immunity. *Frontiers in Immunology*, **2017**, 8, 1968	8.2	49
50	Conserved Inhibition of Neutrophil Extracellular Trap Release by Clinical Biofilms. *Journal of Fungi (Basel, Switzerland)*, **2017**, 3,	5.4	18
49	Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation. *Journal of Autoimmunity*, **2017**, 80, 39-47	15	51
48	The Role of Biofilm Matrix in Mediating Antifungal Resistance **2017**, 369-384		2
47	Blastomyces dermatitidis serine protease dipeptidyl peptidase IVA (DppIVA) cleaves ELR CXC chemokines altering their effects on neutrophils. *Cellular Microbiology*, **2017**, 19, e12741	3.8	5
46	Mechanisms involved in the triggering of neutrophil extracellular traps (NETs) by Candida glabrata during planktonic and biofilm growth. *Scientific Reports*, **2017**, 7, 13065	4.7	38
45	Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3152-5	5.6	13
44	Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications. *Infectious Disease Clinics of North America*, **2016**, 30, 51-83	6.2	169
43	The HostТs Reply to Candida Biofilm. *Pathogens*, **2016**, 5,	4.4	31
42	The Extracellular Matrix of Candida albicans Biofilms Impairs Formation of Neutrophil Extracellular Traps. *PLoS Pathogens*, **2016**, 12, e1005884	7.4	73

41	Community participation in biofilm matrix assembly and function. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 4092-7	11.1	96
40	Host contributions to construction of three device-associated Candida albicans biofilms. *Infection and Immunity*, **2015**, 83, 4630-8	3.6	43
39	Fungal Biofilms:In Vivo Models for Discovery of Anti-Biofilm Drugs **2015**, 33-49		2
38	An expanded regulatory network temporally controls Candida albicans biofilm formation. *Molecular Microbiology*, **2015**, 96, 1226-39	4	101
37	Fungal Biofilms: In Vivo Models for Discovery of Anti-Biofilm Drugs. *Microbiology Spectrum*, **2015**, 3,	8.4	44
36	Novel entries in a fungal biofilm matrix encyclopedia. *MBio*, **2014**, 5, e01333-14	7.6	187
35	Future directions for anti-biofilm therapeutics targeting Candida. *Expert Review of Anti-Infective Therapy*, **2014**, 12, 375-82	5.3	58
34	Rat indwelling urinary catheter model of Candida albicans biofilm infection. *Infection and Immunity*, **2014**, 82, 4931-40	3.6	29
33	The Role of Biofilm Matrix in Mediating Antifungal Resistance **2014**, 1-14		
32	A recently evolved transcriptional network controls biofilm development in Candida albicans. *Cell*, **2012**, 148, 126-38	54.5	467
31	Comparative analysis of Candida biofilm quantitation assays. *Medical Mycology*, **2012**, 50, 214-8	3.8	62
30	Modeling of fungal biofilms using a rat central vein catheter. *Methods in Molecular Biology*, **2012**, 845, 547-56	1.4	13
29	A Candida biofilm-induced pathway for matrix glucan delivery: implications for drug resistance. *PLoS Pathogens*, **2012**, 8, e1002848	7.4	184
28	Portrait of Candida albicans adherence regulators. *PLoS Pathogens*, **2012**, 8, e1002525	7.4	155
27	Identification and characterization of antifungal compounds using a Saccharomyces cerevisiae reporter bioassay. *PLoS ONE*, **2012**, 7, e36021	3.6	27
26	Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. *Eukaryotic Cell*, **2011**, 10, 1660-9		112
25	Hsp90 governs dispersion and drug resistance of fungal biofilms. *PLoS Pathogens*, **2011**, 7, e1002257	7.4	191
24	Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis. *Eukaryotic Cell*, **2011**, 10, 803-19		80

23	Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by tetrazolium salt assay. *Journal of Clinical Microbiology*, **2011**, 49, 1426-33	9.4	104
22	Application of the systematic "DAmP" approach to create a partially defective C. albicans mutant. *Fungal Genetics and Biology*, **2011**, 48, 1056-61	3.7	11
21	Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3505-8	5.6	150
20	Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. *Journal of Infectious Diseases*, **2010**, 202, 171-5	6.8	190
19	Development and validation of an in vivo Candida albicans biofilm denture model. *Infection and Immunity*, **2010**, 78, 3650-9	3.6	118
18	Biofilm matrix regulation by Candida albicans Zap1. *PLoS Biology*, **2009**, 7, e1000133	9.4	230
17	Time course global gene expression analysis of an in vivo Candida biofilm. *Journal of Infectious Diseases*, **2009**, 200, 307-13	6.8	127
16	Review of techniques for diagnosis of catheter-related Candida biofilm infections. *Current Fungal Infection Reports*, **2008**, 2, 237-243	1.3	4
15	Complementary adhesin function in C. albicans biofilm formation. *Current Biology*, **2008**, 18, 1017-24	6.1	240
14	Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1127-32	5.6	176
13	Reduced biocide susceptibility in Candida albicans biofilms. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 3411-3	5.6	53
12	Beta -1,3 glucan as a test for central venous catheter biofilm infection. *Journal of Infectious Diseases*, **2007**, 195, 1705-12	6.8	73
11	Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 510-20	5.6	295
10	Function of Candida albicans adhesin Hwp1 in biofilm formation. *Eukaryotic Cell*, **2006**, 5, 1604-10		268
9	Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2374-83	5.6	63
8	In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 2384-94	5.6	34
7	Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. *PLoS Pathogens*, **2006**, 2, e63	7.4	381
6	Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole. *Antimicrobial Agents and Chemotherapy*, **2006** , 50, 1311-9	5.6	37

5	Candida albicans biofilm development, modeling a host-pathogen interaction. *Current Opinion in Microbiology*, **2006**, 9, 340-5	7.6	162
4	Imaging of the Development and Therapeutic Response of an In Vivo Fungal Catheter Biofilm. *Microscopy Today*, **2005**, 13, 30-33	0.4	
3	Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. *Infection and Immunity*, **2004**, 72, 6023-31	3.6	295
2	ROSA26 mice carry a modifier of Min-induced mammary and intestinal tumor development. *Mammalian Genome*, **2000**, 11, 1058-62	3.1	3
1	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use343-371		3